CA2309206A1 - Methodes de traitement de tumeurs et de cellules tumorales faisant appel a des lymphocytes t actives ex vivo - Google Patents

Methodes de traitement de tumeurs et de cellules tumorales faisant appel a des lymphocytes t actives ex vivo Download PDF

Info

Publication number
CA2309206A1
CA2309206A1 CA002309206A CA2309206A CA2309206A1 CA 2309206 A1 CA2309206 A1 CA 2309206A1 CA 002309206 A CA002309206 A CA 002309206A CA 2309206 A CA2309206 A CA 2309206A CA 2309206 A1 CA2309206 A1 CA 2309206A1
Authority
CA
Canada
Prior art keywords
cells
mammal
population
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002309206A
Other languages
English (en)
Inventor
David N. Liebowitz
Carl June
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2309206A1 publication Critical patent/CA2309206A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002309206A 1997-11-10 1998-11-10 Methodes de traitement de tumeurs et de cellules tumorales faisant appel a des lymphocytes t actives ex vivo Abandoned CA2309206A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6503197P 1997-11-10 1997-11-10
US60/065,031 1997-11-10
PCT/US1998/023954 WO1999024045A1 (fr) 1997-11-10 1998-11-10 METHODES DE TRAITEMENT DE TUMEURS ET DE CELLULES TUMORALES FAISANT APPEL A DES LYMPHOCYTES T ACTIVES $i(EX VIVO)

Publications (1)

Publication Number Publication Date
CA2309206A1 true CA2309206A1 (fr) 1999-05-20

Family

ID=22059894

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002309206A Abandoned CA2309206A1 (fr) 1997-11-10 1998-11-10 Methodes de traitement de tumeurs et de cellules tumorales faisant appel a des lymphocytes t actives ex vivo

Country Status (6)

Country Link
EP (1) EP1030674A1 (fr)
JP (1) JP2001522806A (fr)
AU (1) AU1395499A (fr)
CA (1) CA2309206A1 (fr)
NO (1) NO20002412L (fr)
WO (1) WO1999024045A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
DK1623017T3 (da) 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
PL2573166T3 (pl) 2004-02-26 2016-11-30 Sposoby otrzymywania komórek T do terapii komórkowej
RU2281783C1 (ru) * 2005-04-06 2006-08-20 ГОУ ВПО "Красноярская государственная медицинская академия Министерства здравоохранения РФ" Способ профилактики послеоперационных гнойно-септических осложнений у больных раком прямой кишки
JP2010032444A (ja) * 2008-07-30 2010-02-12 Olympus Corp 生体組織処理装置
US9233156B2 (en) 2011-05-03 2016-01-12 Immunovative Therapies Ltd. Induction of IL-12 using immunotherapy
CA2838041C (fr) 2011-05-03 2018-09-25 Immunovative Therapies, Ltd. Procedes de manipulation de medicaments biologiques contenant des cellules vivantes
CA3033911A1 (fr) * 2016-08-26 2018-03-01 Juno Therapeutics, Inc. Procedes de denombrement de particules presentes dans une composition cellulaire
EP3644728B1 (fr) * 2017-06-28 2022-08-03 Sci-Group AS Congélation d'un matériau biologique
KR102831399B1 (ko) 2018-02-28 2025-07-08 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물에 존재하는 입자를 검출하는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267615A3 (fr) * 1986-11-13 1989-05-03 Sloan-Kettering Institute For Cancer Research Compositions et méthodes pour le traitement du cancer utilisant d'une part un anticorps monoclonal contre le ganglioside GD3 et d'autre part l'IL-2
DE69333580D1 (de) * 1992-04-07 2004-09-09 Univ Michigan Immunregulation über die cd28-route
ES2240962T3 (es) * 1993-06-04 2005-10-16 The United States Of America As Represented By The Secretary Of The Navy Metodo para estimular selectivamente la proliferacion de celulas t.
CA2227327A1 (fr) * 1995-07-25 1997-02-13 Celltherapy, Inc. Immunotherapie par cellules autologues: compositions cellulaires , methodes et application au traitement d'une maladie humaine

Also Published As

Publication number Publication date
JP2001522806A (ja) 2001-11-20
EP1030674A1 (fr) 2000-08-30
NO20002412L (no) 2000-07-07
AU1395499A (en) 1999-05-31
WO1999024045A1 (fr) 1999-05-20
NO20002412D0 (no) 2000-05-09

Similar Documents

Publication Publication Date Title
US6242579B1 (en) Antigen found on a small subset of human hematopoietic cells which binds to monoclonal antibody MG1
Brett et al. Repopulation of blood lymphocyte sub‐populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH‐1H
CA2309206A1 (fr) Methodes de traitement de tumeurs et de cellules tumorales faisant appel a des lymphocytes t actives ex vivo
WO1998021334A9 (fr) Anticorps mg1 reconnaissant un petit sous-ensemble de cellules hematopoietiques humaines
US20050118142A1 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
AU678179B2 (en) Methods for positive immunoselection of stem cells
JP7262568B2 (ja) 免疫エフェクター細胞を使用して腫瘍を治療する方法
US20040016007A1 (en) Chimeric mouse having immunity constructed by using human cd34-positive cells and use thereof
IL273757B1 (en) Expansion and use of expanded nk cell fractions
Natarajan et al. CD4 depletion or CD40L blockade results in antigen-specific tolerance in a red blood cell alloimmunization model
JP2006528627A (ja) アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物
US8394368B2 (en) Method for producing a composition for promoting survival of transplanted hematopoietic stem cell
Abonour et al. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma
Van Gool et al. Expression of B7-2 (CD86) molecules by Reed–Sternberg cells of Hodgkin’s disease
El-Kassas et al. Revolutionizing medicine: Exploring the breakthroughs in liver xenotransplantation
Cowan et al. Tolerance induction post in utero stem cell transplantation
Pamphilon ES02. 02 Stem-cell harvesting and manipulation.
JP7094100B2 (ja) ＴＣＲａｂ陽性細胞およびＣＤ４５ＲＡ陽性細胞を枯渇させた細胞組成物
CN100390264C (zh) 一种设备
Petrányi et al. Tolerance Induction: Historical and Scientific Backround and Recent Development in Clinical Practice.
HK40061392A (en) METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY
Quinones Cellular Engineering of the Hematopoietic Graft
Hornstein Generation of cytotoxic T-lymphocytes by allogeneic platelets in vitro
Brouard Anti-CD28 Antibody-Induced Kidney Allograft Tolerance Related to Tryptophan Degradation and TCR-Class II-B7+ Regulatory Cells
Desmarets Minor antigens on transfused red blood cells in immunity and tolerance

Legal Events

Date Code Title Description
FZDE Discontinued